875 related articles for article (PubMed ID: 28294313)
1. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
4. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
5. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
6. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.
Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H
Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.
Su H; Li B; Zheng L; Wang H; Zhang L
Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282
[TBL] [Abstract][Full Text] [Related]
8. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
10. α-Galactosylceramide-activated murine NK1.1(+) invariant-NKT cells in the myometrium induce miscarriages in mice.
Ichikawa T; Negishi Y; Shimizu M; Takeshita T; Takahashi H
Eur J Immunol; 2016 Aug; 46(8):1867-77. PubMed ID: 27198610
[TBL] [Abstract][Full Text] [Related]
11. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
12. [Inducing hepatocellular carcinoma-specific cytotoxic T lymphocyte response using formed by fusion of FastDCs and allogeneic human hepatocellular carcinoma cells].
Guan X; Leng XS; Peng JR; Wei YH; Wang H; Yuan L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3332-6. PubMed ID: 16409838
[TBL] [Abstract][Full Text] [Related]
13. Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice.
Negishi Y; Ichikawa T; Takeshita T; Takahashi H
Eur J Immunol; 2018 Jun; 48(6):937-949. PubMed ID: 29520760
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
15. Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Transl Oncol; 2019 May; 21(5):636-645. PubMed ID: 30368725
[TBL] [Abstract][Full Text] [Related]
16. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
17. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma.
Liu H; Chen L; Liu J; Meng H; Zhang R; Ma L; Wu L; Yu S; Shi F; Li Y; Zhang L; Wang L; Feng S; Zhang Q; Peng Y; Wu Q; Liu C; Chang X; Yang L; Uemura Y; Yu X; Liu T
Cancer Lett; 2017 Dec; 411():182-190. PubMed ID: 28947140
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells cross-talk with tumour antigen-specific CD8
Eiraku Y; Terunuma H; Yagi M; Deng X; Nicol AJ; Nieda M
Clin Exp Immunol; 2018 Oct; 194(1):54-66. PubMed ID: 30009488
[TBL] [Abstract][Full Text] [Related]
20. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]